Navigation Links
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Date:6/7/2012

ogy practice groups, and health maintenance organizations in the United States, Canada, Puerto Rico, Australia, and Ireland.  At those sites and their satellites, more than 5000 physicians, nurses, and other medical professionals conduct NSABP treatment and prevention trials.

In addition to Dr. Jacobs, another member of the SAB, an oncologist specializing in comparative effectiveness studies of targeted therapies and biomarkers, mathematical and statistical prognostic and predictive models, and advanced methods of evidence synthesis in support of clinical practice guidelines, will attend the meeting.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express we
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
4. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
5. Generex Secures Commitments for $3.6M Capital Raise
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... , - Company Also Granted Expansion of Prophylaxis Therapy Label ... , EXTON, Pa., June 4 ViroPharma Incorporated (Nasdaq: ... Complete Response letter from the U.S. Food and Drug Administration ... Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute ...
... SYDNEY, June 3 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... had raised A$47 million through a placement to,Australian and ... company,s balance sheet as Pharmaxis moves toward,the European and ... , Pharmaxis will issue 20 ...
... 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 11:30 am ET on Wednesday, June 10, 2009 at ... held in New York City. , , The presentation ...
Cached Biology Technology:ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 2ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 3ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 4ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 5Pharmaxis Announces Placement of $47 Million and Share Purchase Plan 2Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 2
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
(Date:7/25/2014)... shows that the age girls reach puberty is influenced by ... which parent contributes the gene. This is the first ... after birth and details of this study were published today ... first period, known as menarche, is a marker for the ... the onset of menses varies between girls, is an inherited ...
(Date:7/25/2014)... Biometrics industry expands and becomes ... technology for online & commerce payments while seeking security ... GOOG ), LifeLock Inc. (NYSE: LOCK ... Inc. (NASDAQ: AAPL ) and Fortinet Inc. ... biometric authentication company focused on the growing m-commerce market, ...
Breaking Biology News(10 mins):New hope for powdery mildew resistant barley 2Could age of first period influence development of diseases in older women? 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... DIEGO Research by the Scripps Translational Science Institute (STSI) ... the chest for up to two weeks does a better ... Holter monitor, which is typically used for 24 hours and ... years. The findings, which were published and made publically ...
... pain reliever in Chinese medicine may be just what the ... key pain-relieving ingredient is a compound known as dehydrocorybulbine (DHCB) ... , a member of the poppy family, according to researchers ... Current Biology on January 2. "Our study reports ...
... cancer, heart disease and other diseases were not enough motivation ... wake-up call: New research published in the January 2014 issue ... smoking disrupts the circadian clock function in both the lungs ... leading to cognitive dysfunction, mood disorders, depression and anxiety. ...
Cached Biology News:Patch outperforms Holter for prolonged heart rhythm tracking 2Plant used in Chinese medicine fights chronic pain 2Want a good night's sleep in the New Year? Quit smoking 2
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: